Received Mar 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | UNK | X028614 | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | UNK | Y005465 | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | Y005878 | OT |
No additional adverse event; VFC immunization coordinator calling to report T/E for PEDVAX HIB , ROTATEQ, VAXNEUVANCE that was administered. T/E date was on 2/18/2025 and PEDVAX HIB , ROTATEQ, VAXNEUVANCE were administered on 2/25/2025. Permission was given to contact HCP; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies and concomitant medications were not reported. On 18-Feb-2025 a temperature excursion of above 32.0 Fahrenheit (F) for a time frame of 2 hours, 12 minutes and 0 seconds occurred. On 25-Feb-2025, the patient was vaccinated with the first dose of Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), lot #Y005878, expiration date: 28-Oct-2025 (strength and dose were not provided); with the first dose of Pneumococcal 15-valent Conjugate Vaccine lot #Y005465, expiration date: 08-Jan-2027 (strength, dose, route of administration and anatomical site of injection were not provided); and with the first dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), lot #X028614, expiration date: 05-Jul-2026 (strength, dose, route of administration and anatomical site of injection were not provided). All vaccines were administered for prophylaxis (Product storage error). No additional adverse event was reported (no adverse event). No previews temperature excursions were reported.